Teyi Pharmaceutical Group (002728) Fundamentals 2026 — P/E 58.6x, Revenue Analysis | SniperIQ
Teyi Pharmaceutical Group (002728) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥4.4B, trading at ¥8.62 on the SHZ. This SniperIQ fundamentals page covers Teyi Pharmaceutical Group's valuation (P/E 58.6x, P/B 2.4x), profitability (net margin 9.0%), revenue (¥916M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Teyi Pharmaceutical Group's market cap?
Teyi Pharmaceutical Group (002728) has a market capitalization of approximately ¥4.4B, trading at ¥8.62 on the SHZ. Market cap moves with the live share price.
What is Teyi Pharmaceutical Group's P/E ratio?
Teyi Pharmaceutical Group's trailing twelve-month P/E ratio is 58.6x, with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Teyi Pharmaceutical Group?
Teyi Pharmaceutical Group runs a net profit margin of 9.0%, a gross margin of 51.8%, and an operating margin of 9.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Teyi Pharmaceutical Group generate?
Teyi Pharmaceutical Group reported revenue of ¥916M for fiscal year 2025, with net income of ¥82M and earnings per share (EPS) of 0.16. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Teyi Pharmaceutical Group pay a dividend?
Teyi Pharmaceutical Group offers a trailing dividend yield of about 1.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Teyi Pharmaceutical Group financially healthy?
Teyi Pharmaceutical Group carries a debt-to-equity ratio of 0.17x and a current ratio of 2.01x, with a market beta of 1.36. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Teyi Pharmaceutical Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Teyi Pharmaceutical Group (002728) the key facts are: market cap ¥4.4B, P/E 58.6x, revenue ¥916M, 52-week range 7.66-15.21. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Teyi Pharmaceutical Group's full fundamentals live
Get Teyi Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.